Hyphens Pharma has reported net profit after tax (NPAT) of $3.2 million for the 1QFY2022 ended March, 49.7% higher than net profit of $2.1 million in the same period the year before.
Revenue increased by 18.5% y-o-y to $39.2 million thanks to contributions from its three business segments, as well as its newly-acquired subsidiary, Novem.
Gross profit increased by 23.9% y-o-y to $15.0 million, with gross profit margin improving 1.7 percentage points y-o-y to 38.4%.
Looking ahead, Hyphens Pharma says it will be focusing on its proprietary brands, continue to seek out acquisition opportunities, boost its investment in digital initiatives and strengthen its specialty pharma portfolio.
As at 9.21am, shares in Hyphens Pharma are trading flat at 28 cents.
